Cargando…

Selective Inhibition of the MK2 Pathway: Data From a Phase IIa Randomized Clinical Trial in Rheumatoid Arthritis

OBJECTIVE: The study objective was to evaluate the safety, tolerability, pharmacodynamics, and preliminary efficacy of ATI‐450 with methotrexate in patients with rheumatoid arthritis (RA). METHODS: A parallel‐assignment, placebo‐controlled, investigator‐blinded/patient‐blinded multicenter study eval...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gordon, David, Kivitz, Alan, Singhal, Atul, Burt, David, Bangs, Madison C., Huff, Emma E., Hope, Heidi Rath, Monahan, Joseph B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926068/ https://www.ncbi.nlm.nih.gov/pubmed/36604812 http://dx.doi.org/10.1002/acr2.11517

Ejemplares similares

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MK2 Inhibitor ATI-450 in Healthy Subjects: A Placebo-Controlled, Randomized Phase 1 Study
por: Gordon, David, et al.
Publicado: (2021)

Nearly Pain-Free Self-administration of Subcutaneous Methotrexate With an Autoinjector: Results of a Phase 2 Clinical Trial in Patients With Rheumatoid Arthritis Who Have Functional Limitations
por: Freundlich, Bruce, et al.
Publicado: (2014)

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
por: Mease, Philip J, et al.
Publicado: (2022)

Tanshinone IIA inhibits osteoclastogenesis in rheumatoid arthritis via LDHC-regulated ROS generation
por: Peng, Qiuwei, et al.
Publicado: (2023)

Disease–Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis
por: Lee, Eun Bong, et al.
Publicado: (2016)

Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study
por: Kivitz, Alan, et al.
Publicado: (2016)

Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment
por: Bessette, Louis, et al.
Publicado: (2017)

A randomized, phase IIa study to assess the systemic exposure of triamcinolone acetonide following injection of extended-release triamcinolone acetonide or traditional triamcinolone acetonide into both knees of patients with bilateral knee osteoarthritis
por: Kivitz, Alan, et al.
Publicado: (2019)

Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study
por: Winthrop, Kevin, et al.
Publicado: (2022)

The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis
por: Kivitz, Alan, et al.
Publicado: (2023)

Inhibitory effect of tanshinone IIA on inflammatory response in rheumatoid arthritis through regulating β-arrestin 2
por: Tang, Jing, et al.
Publicado: (2019)

Phase 1 study of TRU-015, a CD20-directed small modular immunopharmaceutical (SMIP™) protein therapeutic, in subjects with rheumatoid arthritis
por: Burge, DJ, et al.
Publicado: (2007)

Assessing usability, label comprehension, pen robustness and pharmacokinetics of a self-administered prefilled autoinjector pen of methotrexate in patients with rheumatoid arthritis
por: Pachon, Jaime A, et al.
Publicado: (2014)

Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA)
por: Bingham, Clifton O, et al.
Publicado: (2015)

An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis
por: Cohen, Stanley, et al.
Publicado: (2019)

Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making
por: Taylor, Peter C, et al.
Publicado: (2020)

Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis
por: Bergman, Martin J., et al.
Publicado: (2020)

Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2023)

Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies
por: Genovese, Mark C., et al.
Publicado: (2020)

Tanshinone IIA promotes the apoptosis of fibroblast-like synoviocytes in rheumatoid arthritis by up-regulating lncRNA GAS5
por: Li, Guoqing, et al.
Publicado: (2018)

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: a phase I/IIa, open-label, non-randomized pilot trial
por: Vij, Ridhima, et al.
Publicado: (2022)

Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study
por: Genovese, Mark C., et al.
Publicado: (2019)

Expression of Concern: Tanshinone IIA promotes the apoptosis of fibroblast-like synoviocytes in rheumatoid arthritis by upregulating lncRNA GAS5
Publicado: (2023)

Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study
por: Visvanathan, Sudha, et al.
Publicado: (2019)

Is juvenile rheumatoid arthritis/juvenile idiopathic arthritis different from rheumatoid arthritis?
por: Prahalad, Sampath, et al.
Publicado: (2002)

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials
por: Vanhoutte, Frédéric, et al.
Publicado: (2017)

Selective inhibition of the p38α MAPK–MK2 axis inhibits inflammatory cues including inflammasome priming signals
por: Wang, Chun, et al.
Publicado: (2018)

Fatigue in rheumatoid arthritis
por: Choy, Ernest H, et al.
Publicado: (2019)

Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study
por: Broadwell, Aaron, et al.
Publicado: (2023)

A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol
por: Curtis, Jeffrey R., et al.
Publicado: (2015)

Poncet's Disease in the Preclinical Phase of Rheumatoid Arthritis
por: Nyo, Myat Tun Lin, et al.
Publicado: (2018)

Irreversible covalent Bruton’s tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial
por: Takeuchi, Tsutomu, et al.
Publicado: (2023)

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
por: Combe, Bernard, et al.
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA
por: Abdallah, Hisham, et al.
Publicado: (2016)

Arthritis Robustus: review of a case of an “abnormal” rheumatoid
por: Prasad, Kajal, et al.
Publicado: (2014)

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
por: Kivitz, Alan, et al.
Publicado: (2014)

71. Paget's disease with rheumatoid arthritis: by chance not providence
por: Deep Rath, Prasan, et al.
Publicado: (2018)

Gene drive inhibition by the anti-CRISPR proteins AcrIIA2 and AcrIIA4 in Saccharomyces cerevisiae
por: Basgall, Erianna M., et al.
Publicado: (2018)

A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma
por: Stover, Elizabeth H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sgs2v1ebjgjhnu8t2690ti4k99